Two front-page stories in the Metro section of Monday’s Washington Post depict protected service providers desperately trying to fight off innovations that might serve customers better and threaten the comfortable incomes of the established providers.
Thalidomide was a drug marketed in the 1950s in West Germany for the treatment of morning sickness and other nausea in pregnant women. However, thousands of women who took thalidomide had babies who were born with limb deformities, and many of those children also died shortly after birth. Can the government justifiably keep thalidomide out […]